Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the CardioMEMS Heart Failure System

Author:

Kapelios Chris J.12,Liori Sotiria1,Bonios Michael2,Abraham William T.3,Filippatos Gerasimos1ORCID

Affiliation:

1. Heart Failure Unit, Department of Cardiology Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens Athens Greece

2. Heart Failure and Transplant Unit Onassis Cardiac Surgery Centre Attica Greece

3. Division of Cardiology The Ohio State University Wexner Medical Center Columbus OH USA

Abstract

AimsPulmonary artery pressure (PAP)‐guided heart failure (HF) management using the CardioMEMS HF System improves patient outcomes in randomized controlled trials (RCTs). Our aim was to systematically assess its impact on outcomes of HF patients receiving the device in a non‐RCT setting.Methods and resultsPubMed, ClinicalTrials.gov and Cochrane Clinical Trial Collection were searched on 8 January 2025. Studies were eligible if they included: (i) pre/post‐comparison of outcomes in patients receiving CardioMEMS; (ii) adult patients diagnosed with HF; (iii) follow‐up ≥6 months, and (iv) report of the primary outcome, i.e. HF hospitalization (HFH) rates. Other outcomes were changes in PAP, New York Heart Association (NYHA) class and quality of life. Quantitative analysis was performed by generating forest plots and calculating pooled means, mean differences and incidence rate ratio (IRR) by random‐effect models, as appropriate. Eight studies with a total of 3306 patients were included. Four studies were single‐arm, open‐label, industry‐funded studies and four real‐world practice studies. Four studies were performed in the US and four in Europe. Significant decreases in systolic PAP (−7.8 mmHg [−10.1 mmHg; −5.6 mmHg]), mean PAP (−5.2 mmHg [−6.7 mmHg; −3.8 mmHg]) and diastolic PAP (−4.4 mmHg [−5.5 mmHg; −3.3 mmHg]) were demonstrated. One year after CardioMEMS implantation, 56% [43%; 67%] of patients were NYHA class I/II with EQ‐5D‐5L visual analogue scale scores being significantly improved from baseline (7.2 [3.5; 10.9]). PAP‐guided HF management was associated with a significant, 61% decrease in HFHs at 1 year (IRR 0.39 [0.31; 0.47]).ConclusionsHeart failure management with CardioMEMS leads to lower PAP, improved functional status and quality of life, and decrease of HFHs at 1 year in patients receiving the device in a real‐life, non‐RCT setting.Systematic review registration:PROSPERO database registration number CRD42025635206.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3